Helixmith Co. Ltd (084990) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Helixmith Co. Ltd (084990) has a cash flow conversion efficiency ratio of -0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.87 Billion ≈ $-1.27 Million USD) by net assets (₩140.28 Billion ≈ $95.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Helixmith Co. Ltd market capitalisation for the company's overall valuation and market capitalisation.
Helixmith Co. Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Helixmith Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Helixmith Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Helixmith Co. Ltd ranked by their cash flow conversion efficiency. Explore Helixmith Co. Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scandium International Mining Corp
F:0E6
|
0.087x |
|
Winix Inc
KQ:044340
|
-0.114x |
|
Nexam Chemical Holding AB
ST:NEXAM
|
-0.024x |
|
Coda Minerals Ltd
AU:COD
|
-0.136x |
|
I Yuan Precision Ind Co Ltd
TWO:2235
|
0.025x |
|
Western Alaska Minerals Corp
V:WAM
|
-0.616x |
|
Fertilizantes Heringer S.A
SA:FHER3
|
-0.065x |
|
Offerpad Solutions Inc
NYSE:OPAD
|
0.197x |
Annual Cash Flow Conversion Efficiency for Helixmith Co. Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Helixmith Co. Ltd from 2010 to 2025. View 084990 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩141.52 Billion ≈ $95.91 Million |
₩-6.90 Billion ≈ $-4.67 Million |
-0.049x | +58.59% |
| 2024-12-31 | ₩142.04 Billion ≈ $96.26 Million |
₩-16.72 Billion ≈ $-11.33 Million |
-0.118x | +30.11% |
| 2023-12-31 | ₩153.72 Billion ≈ $104.18 Million |
₩-25.89 Billion ≈ $-17.54 Million |
-0.168x | +10.38% |
| 2022-12-31 | ₩216.80 Billion ≈ $146.92 Million |
₩-40.74 Billion ≈ $-27.61 Million |
-0.188x | -10.96% |
| 2021-12-31 | ₩225.35 Billion ≈ $152.72 Million |
₩-38.16 Billion ≈ $-25.86 Million |
-0.169x | +2.54% |
| 2020-12-31 | ₩276.30 Billion ≈ $187.25 Million |
₩-48.01 Billion ≈ $-32.54 Million |
-0.174x | +17.25% |
| 2019-12-31 | ₩195.57 Billion ≈ $132.53 Million |
₩-41.07 Billion ≈ $-27.83 Million |
-0.210x | -108.92% |
| 2018-12-31 | ₩133.87 Billion ≈ $90.72 Million |
₩-13.46 Billion ≈ $-9.12 Million |
-0.101x | -538.11% |
| 2017-12-31 | ₩164.45 Billion ≈ $111.45 Million |
₩-2.59 Billion ≈ $-1.76 Million |
-0.016x | -9.76% |
| 2016-12-31 | ₩170.93 Billion ≈ $115.84 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.014x | -188.31% |
| 2015-12-31 | ₩67.20 Billion ≈ $45.54 Million |
₩1.09 Billion ≈ $740.06K |
0.016x | +9598.28% |
| 2013-12-31 | ₩66.97 Billion ≈ $45.38 Million |
₩11.22 Million ≈ $7.60K |
0.000x | +100.30% |
| 2012-12-31 | ₩64.45 Billion ≈ $43.68 Million |
₩-3.58 Billion ≈ $-2.43 Million |
-0.056x | -26.50% |
| 2011-12-31 | ₩49.78 Billion ≈ $33.74 Million |
₩-2.19 Billion ≈ $-1.48 Million |
-0.044x | +12.11% |
| 2010-12-31 | ₩52.72 Billion ≈ $35.73 Million |
₩-2.64 Billion ≈ $-1.79 Million |
-0.050x | -- |
About Helixmith Co. Ltd
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological… Read more